GLP-1 Weight Loss Drugs May Reduce Activity Levels, Study Finds
A new analysis of fitness tracker data reveals that people taking popular weight-loss drugs like Ozempic and Wegovy are losing pounds but may be moving less overall, raising questions about long-term activity patterns.
Unexpected Finding: Weight Loss Drugs and Reduced Movement
People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. This counterintuitive finding emerged from an analysis of real-world health data and challenges assumptions about how these medications affect daily behavior.
How Researchers Measured Activity
Researchers analyzing Fitbit data found that daily activity levels declined among users of these medications. The study used objective tracking data from millions of users, providing a comprehensive view of how these drugs affect real-world behavior rather than relying on patient self-reporting alone.
Why This Matters
GLP-1 receptor agonists work partly by reducing appetite and increasing feelings of fullness, which helps people eat less and lose weight. However, the reduced activity levels suggest these drugs may have broader effects on motivation, energy levels, or overall physical engagement. Some researchers speculate that weight loss itself might reduce motivation to exercise, or that the medications may have metabolic effects that reduce energy.
Health Implications and Questions
While weight loss remains a significant health benefit, especially for people with obesity or type 2 diabetes, the reduced movement raises concerns about cardiovascular fitness, muscle preservation, and other markers of physical health. Medical professionals are monitoring these trends closely as GLP-1 drugs become increasingly popular. More research is needed to understand whether the movement reduction is temporary, permanent, or avoidable with targeted interventions.